Carbapenem-Based Antibiotics Market Growth Accelerates as Healthcare Battles Resistant Bacteria The Carbapenem-Based Antibiotics Market is gaining significant momentum as the global burden of multidrug-resistant (MDR) bacterial infections continues to rise. According to the latest market analysis, the carbapenem-based antibiotics market size is projected to grow from US$ 3,964.57 million in 2021 to US$ 5,346.62 million by 2028, registering a CAGR of 4.4% during 2021–2028. As antibiotic resistance becomes one of the most pressing public health threats worldwide, the need for effective, broad-spectrum antibiotics—particularly carbapenems—has never been more critical. Read More @ https://www.theinsightpartners.com/reports/carbapenem-based-antibiotics-market Carbapenems, known for their ability to combat severe and complicated bacterial infections, remain the cornerstone of treatment in hospital settings. With rising cases of hospital-acquired infections, increased surgical procedures, and greater demand for advanced antimicrobial therapies, the Carbapenem-Based Antibiotics Market is expected to witness consistent expansion over the forecast period. Market Overview Carbapenems are widely recognized for their efficacy against Gram-negative and Gram-positive pathogens, including resistant strains. Market growth is propelled by increasing prevalence of chronic illnesses, rising nosocomial infection rates, and the continued development of next-generation carbapenem formulations. Healthcare systems worldwide are facing escalating pressure to manage MDR infections, and carbapenems continue to serve as last-line agents in various therapeutic settings. Growing pharmaceutical R&D efforts, along with advancements in drug delivery technologies and the push for accelerated approvals of antimicrobial therapies, are also contributing to market expansion. Additionally, greater access to hospital pharmacy services and increasing availability through online and retail pharmacy channels are supporting stronger market penetration. Segmentation Analysis By Type Meropenem Doripenem Imipenem Tebipenem By Indication Bacterial Meningitis Acute Pelvic Infections Respiratory Tract Infections Intra-Abdominal Infections Urinary Tract Infections By Distribution Channel Retail Pharmacies Online Pharmacies Hospital Pharmacies Market Insights Rising Prevalence of Gram-Negative Bacterial Infections Gram-negative bacterial infections, such as urinary tract infection (UTI), pneumonia, bloodstream infections, wound or surgical site infections, and meningitis, are commonly acquired by patients during their hospital stays. These infections are generally known as hospital-acquired infections (HAI). Infections such as UTI and pneumonia are common in patients admitted to intensive care units. According to the US National Healthcare Safety Network, 30% of HAIs are caused by gram-negative bacteria, ~45% are due to UTI, and ~47% are by ventilator-associated pneumonia (VAP). The prevalence of infectious diseases caused by gram-negative bacteria is rapidly increasing. Market Leaders and Key Company Profiles Pfizer Inc. Savior Lifetec Sumitomo Dainippon Pharma Co., Ltd. Merck & Co., Inc. Gland Pharma Limited Aurobindo Pharma Ltd Daewoong Pharmaceutical Co.,Ltd, Iterum Therapeutics plc ACS Dobfar S.p.A In addition, gram-negative bacterial infections are resistant to multiple drugs and have developed better resistance to available antibiotics. Antimicrobial resistance (AMR) has become a global threat to modern medicine. Therefore, constant monitoring of emerging trends is required for the clinical isolates. A group of researchers in Latvia, Europe, has studied the progression of AMR for different gram-negative bacteria. As per the research article published by them in the MDPI journal in June 2021, carbapenem-based antibiotics such as Meropenem and Ertapenem were the most effective against gram-negative bacteria, showing 3% and 5.4% resistance rates, respectively. These antibiotics are globally accepted as a treatment for gram-negative bacteria. Therefore, it is estimated that the high demand for carbapenem-based antibiotics is likely to continue in the coming years. Conclusion The Carbapenem-Based Antibiotics Market stands at a vital juncture as antimicrobial resistance continues to escalate globally. With strong clinical relevance, increasing healthcare demand, and expanding pharmaceutical efforts, carbapenems will remain indispensable in managing severe bacterial infections. Forecasted steady market growth through 2028 reflects rising global dependence on these powerful antibiotics, reinforcing their critical role in modern infection management. Related Reports: Biotechnology Instruments Market - https://www.theinsightpartners.com/reports/biotechnology-instruments-market Cryostat Microbiome Equipment Market - https://www.theinsightpartners.com/reports/cryostat-microbiome-equipment-market Biotechnology Market - https://www.theinsightpartners.com/reports/biotechnology-market Citrus Bioflavonoids Market - https://www.theinsightpartners.com/reports/citrus-bioflavonoids-market About Us: The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact Us: If you have any queries about this report or if you would like further information, please get in touch with us: Contact Person: Ankit Mathur E-mail: ankit.mathur@theinsightpartners.com Phone: +1-646-491-9876

Bioprocessing Market Transforms Therapeutic Production with Breakthrough Technologies The Bioprocessing Market continues to experience transformative growth driven by rising demand for biologics, advancements in biomanufacturing technologies, and expanding applications across pharmaceuticals, biotechnology, and cell & gene therapy. According to the latest industry projections, the bioprocessing market size is expected to increase from US$ 25.35 billion in 2023 to US$ 72.55 billion by 2031, growing at a robust CAGR of 14.0% during 2023–2031. As global healthcare systems evolve and precision biologics become essential for advanced therapies, bioprocessing stands at the center of innovation, efficiency, and scalable production. Market Overview Bioprocessing technologies play a critical role in the development and manufacturing of biologically derived products, including monoclonal antibodies, vaccines, therapeutic proteins, and cell- and gene-based treatments. The growing prevalence of chronic diseases, rising adoption of personalized medicine, and ongoing expansion of biopharmaceutical R&D investments are collectively shaping the positive trajectory of the Bioprocessing Market. Companies are increasingly shifting toward automated, flexible, and scalable bioprocessing platforms that allow faster production cycles and reduced operational costs. Innovations such as single-use technologies, advanced bioreactors, and fully integrated continuous bioprocessing systems are transforming traditional workflows and enabling faster time-to-market for life-saving therapies. Read More @ https://www.theinsightpartners.com/reports/bioprocessing-market Segmentation Analysis By Product Instruments Consumables and Accessories By Scale Of Operation Commercial Operations Clinical Operations By Process Downstream Bioprocess Upstream Bioprocess By Application Monoclonal Antibodies Vaccines Recombinant Protein Cell and Gene Therapy Analyst Perspective: The report includes growth prospects owing to the current bioprocessing market trends and their foreseeable impact during the forecast period. The growing cases of chronic diseases are one of the major factors increasing the demand for new drugs, which creates a need for bioprocessing. In addition, personalized treatment of diseases such as cancer increases the demand for various bioprocessing technologies, including cell therapy. The importance of research and development in the life sciences industry has been greatly promoted in recent years. Due to this trend, government support for the pharmaceutical and biotech industries is also increasing. Additionally, a growing focus on preventative measures and alternative medicines for specific applications drives the market for bioprocessing. Additionally, increasing investment in new technologies to overcome performance and quality issues associated with manufacturing bioprocess products is expected to drive bioprocessing market growth. Market Leaders and Key Company Profiles Getinge AB, Thermo Fisher Scientific Inc, Sartorius AG, Corning Inc, Bio-Rad Laboratories Inc. Merck KGaA, 3M Co, Eppendorf SE, Repligen Corp, Entegris Inc, Market Driver Increasing Prevalence of Chronic Diseases Propel Market Growth The sedentary life of older people has boosted the prevalence of lifestyle disorders, such as obesity and diabetes. Inherited genes can also express these conditions along with other health concerns such as cardiovascular disease (CVDs), Alzheimer’s disease, and depression. As per the National Council on Aging, Inc., 80% of adults (aged 65 and more) are reported to suffer from at least one chronic condition in their lifetime. According to the Centers for Disease Control and Prevention (CDC), approximately 6 of 10 people in the US suffered from at least one serious disease, and 4 of 10 people had two or more chronic conditions in 2020. CVDs, such as angina pectoris, atherosclerosis, and acute myocardial infarction caused because of hectic lifestyles, are among the significant causes of mortality across the world. As per the World Heart Foundation, mortality caused due to CVD has surged by 60% over the past 30 years (1990–2020). 20.5 million deaths were recorded in 2021 due to CVDs. Diabetes is one of the life-threatening chronic diseases with no functional cure. According to the International Diabetes Federation, the number of diabetic cases in North America is anticipated to grow from 46 million in 2017 to 62 million by 2045. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, 19.3 million cancer cases were reported across the world. The number of cases was significantly high in the US, China, and India. The GLOBOCAN further estimates that cancer cases in India would reach ~2.08 million by 2040, representing a rise of 57.5% from 2020. Similarly, as per the World Health Organization data published in February 2022, ~10 million people across the world have succumbed to death due to cancer. An upsurge in the incidence of cancer indicates the need for innovative cancer treatments. Monoclonal antibodies represent a promising class of targeted anticancer agents that enhance the natural ability of immune systems to suppress cancer cell activity and eliminate cancer cells. Antibody–drug conjugates (ADCs) have also shown promising results in cancer treatment. Conclusion The Bioprocessing Market is poised for exceptional growth through 2031 as technological innovations, rising biologics production, and expanding therapeutic pipelines continue to reshape the global biomanufacturing landscape. With strong market value prospects and increasing adoption of high-performance bioprocessing solutions, the sector remains essential to the future of advanced therapeutics, precision medicine, and global healthcare resilience. Related Reports: Biostimulants Market - https://www.theinsightpartners.com/reports/biostimulants-market Biopsy Devices Market - https://www.theinsightpartners.com/reports/biopsy-devices-market Biorationals Market - https://www.theinsightpartners.com/reports/biorationals-market Bioproduction Market - https://www.theinsightpartners.com/reports/bioproduction-market About Us: The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact Us: If you have any queries about this report or if you would like further information, please get in touch with us: Contact Person: Ankit Mathur E-mail: ankit.mathur@theinsightpartners.com Phone: +1-646-491-9876